What is 4baseCare?
Founded in 2018 and headquartered in Karnataka, India, 4baseCare operates at the vanguard of precision oncology. The company specializes in developing affordable, accessible diagnostic and therapeutic solutions that utilize next-generation sequencing and digital health technology. By personalizing patient care through data-driven insights, 4baseCare addresses critical gaps in cancer treatment, positioning itself as a pivotal player in the global health-tech ecosystem. Its market position is reinforced by a commitment to democratizing high-end genomic testing, ensuring that advanced oncology care is not limited by geographic or economic barriers.
How much funding has 4baseCare raised?
4baseCare has raised a total of $22M across 4 funding rounds:
Other Financing Round
$2M
Other Financing Round
$6M
Unspecified
$1M
Series B
$13M
Other Financing Round (2021): $2M with participation from First In Ventures, Season Two Ventures, Mount Judi Ventures LLP, and growX ventures
Other Financing Round (2024): $6M led by Yali Capital Partners
Unspecified (2024): $1M supported by Infosys
Series B (2026): $13M featuring Growx, Kk
Key Investors in 4baseCare
Infosys
Infosys is a global provider of next-generation digital services and consulting, specializing in AI, automation, and data analytics to drive enterprise transformation.
Yali Capital Partners
Yali Capital Partners is an investment banking firm that provides strategic financial support and capital allocation for emerging growth companies.
growX ventures
growX ventures is an early-stage venture capital firm focused on supporting technology-driven startups with high growth potential in the Indian market.
What's next for 4baseCare?
With the infusion of this latest capital, 4baseCare is poised to accelerate its research and development pipeline and expand its operational footprint. The strategic focus will likely shift toward scaling its digital health platform and enhancing its genomic database to improve diagnostic accuracy. As the company transitions into a more mature enterprise-level phase, the emphasis will remain on clinical validation and the integration of AI-driven analytics to further refine personalized treatment protocols. This funding round provides the necessary runway to solidify its leadership in the precision medicine market while exploring new international partnerships.
See full 4baseCare company page
